Health Care Fund
Daily price w/o sales charge as of 10/27/2020
$20.27
$0.11
YTD Returns w/o sales charge as of 10/27/2020
25.12%
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 09/30/2020
- Total Net Assets
- $3.52 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 8.67%
- Fund Net Expense Ratio
- 0.70%
- Number of Holdings
- 88
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | 20.56% | 40.20% | - | - | - | 25.44% |
| Lipper Category Avg. Health/Biotechnology Funds | 11.34% | 32.36% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | 6.94% | 21.62% | - | - | - | 17.99% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | 20.56% | 40.20% | - | - | - | 25.44% |
| Lipper Category Avg. Health/Biotechnology Funds | 11.34% | 32.36% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | 6.94% | 21.62% | - | - | - | 17.99% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM
Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | 20.56% | 40.20% | - | - | - | 25.44% |
| Lipper Category Avg. Health/Biotechnology Funds | 11.34% | 32.36% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | 6.94% | 21.62% | - | - | - | 17.99% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | 20.56% | 40.20% | - | - | - | 25.44% |
| Lipper Category Avg. Health/Biotechnology Funds | 11.34% | 32.36% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | 6.94% | 21.62% | - | - | - | 17.99% |
Fund Expense Ratio :
Gross 8.67%
Net 0.70%
| Year | Fund Returns | MSCI ACWI Health Care Index (Net) |
|---|
| 2019 | 8.07% | 22.67% |
| Year | Q1 | Q2 | Q3 | Q4 | Yearly Returns |
|---|
| 2020 | -11.30% | 21.57% | 11.79% | - | 25.12% |
| 2019 | - | - | - | 16.29% | 8.07% |
NAV Historical Prices
| Date | Net Asset Value |
|---|
Portfolio
Portfolio
Portfolio Details as of 09/30/2020
- Total Net Assets
- $3.52 M
- Number of Holdings
- 88
- Weighted Average Market Cap.
- 72.8 B
- P/B Ratio
- 6.7x
- P/E Ratio
- 29.1x
To view definitions for the above Portfolio Details, Click here.
| Holding | Sector | Assets |
|---|
| Abbott Laboratories | Health Care | 3.4% |
| UnitedHealth Group, Inc. | Health Care | 3.4% |
| Thermo Fisher Scientific, Inc. | Health Care | 3.3% |
| Danaher Corp. | Health Care | 3.1% |
| Novo Nordisk A/S | Health Care | 2.9% |
| Vertex Pharmaceuticals, Inc. | Health Care | 2.9% |
| Merck & Co., Inc. | Health Care | 2.7% |
| AstraZeneca plc | Health Care | 2.6% |
| Amgen, Inc. | Health Care | 2.4% |
| Zoetis, Inc. | Health Care | 2.2% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
| Holding | Sector | Assets |
|---|
| Abbott Laboratories | Health Care | 3.6% |
| UnitedHealth Group, Inc. | Health Care | 3.6% |
| Thermo Fisher Scientific, Inc. | Health Care | 3.4% |
| Merck & Co., Inc. | Health Care | 2.9% |
| AstraZeneca plc | Health Care | 2.9% |
| Vertex Pharmaceuticals, Inc. | Health Care | 2.6% |
| Danaher Corp. | Health Care | 2.6% |
| Novo Nordisk A/S | Health Care | 2.6% |
| Amgen, Inc. | Health Care | 2.6% |
| Zoetis, Inc. | Health Care | 2.3% |
| Intuitive Surgical, Inc. | Health Care | 2.0% |
| Lonza Group AG | Health Care | 1.8% |
| Immunomedics, Inc. | Health Care | 1.7% |
| Roche Holding Ltd. AG | Health Care | 1.7% |
| Johnson & Johnson, Inc. | Health Care | 1.5% |
| Twist Bioscience Corp | Health Care | 1.5% |
| Genmab A/S | Health Care | 1.5% |
| Boston Scientific Corp. | Health Care | 1.5% |
| CVS Caremark Corp. | Health Care | 1.5% |
| UCB SA | Health Care | 1.4% |
| DexCom, Inc. | Health Care | 1.4% |
| Bio-Rad Laboratories, Inc. | Health Care | 1.2% |
| Sartorius Stedim Biotech | Health Care | 1.2% |
| Seattle Genetics, Inc. | Health Care | 1.2% |
| IDEXX Laboratories, Inc. | Health Care | 1.2% |
| Chewy Inc | Consumer Discretionary | 1.1% |
| Natera, Inc. | Health Care | 1.1% |
| Repligen Corp. | Health Care | 1.1% |
| Teladoc Health | Health Care | 1.0% |
| Nevro Corp. | Health Care | 1.0% |
| Veeva Systems, Inc. | Health Care | 1.0% |
| Regeneron Pharmaceuticals, Inc. | Health Care | 1.0% |
| Mirati Therapeutics, Inc. | Health Care | 1.0% |
| TG Therapeutics, Inc. | Health Care | 1.0% |
| Arena Pharmaceuticals, Inc. | Health Care | 0.9% |
| Catalent Inc | Health Care | 0.9% |
| Insulet Corp. | Health Care | 0.9% |
| Argenx SE | Health Care | 0.9% |
| Axonics Modulation Technologies Inc | Health Care | 0.9% |
| 10X Genomics Inc | Health Care | 0.9% |
| MyoKardia Inc | Health Care | 0.9% |
| Turning Point Therapeutics Inc | Health Care | 0.9% |
| Sarepta Therapeutics, Inc. | Health Care | 0.9% |
| Centene Corp. | Health Care | 0.9% |
| Sanofi | Health Care | 0.8% |
| Align Technology, Inc. | Health Care | 0.8% |
| Iovance Biotherapeutics Inc | Health Care | 0.8% |
| Charles River Laboratories International, Inc. | Health Care | 0.8% |
| Rocket Pharmaceuticals Inc | Health Care | 0.8% |
| Zimmer Biomet Holdings, Inc. | Health Care | 0.7% |
| Alcon Inc | Health Care | 0.7% |
| Tecan Group AG | Health Care | 0.7% |
| Cooper Cos., Inc. | Health Care | 0.7% |
| Edwards Lifesciences Corp. | Health Care | 0.7% |
| Quanterix Corp | Health Care | 0.7% |
| Penumbra, Inc. | Health Care | 0.6% |
| ChemoCentryx Inc | Health Care | 0.6% |
| Guardant Health Inc | Health Care | 0.6% |
| Acceleron Pharma, Inc. | Health Care | 0.6% |
| Bridgebio Pharma Inc | Health Care | 0.6% |
| Blueprint Medicines Corp. | Health Care | 0.6% |
| Insmed, Inc. | Health Care | 0.6% |
| Silk Road Medical Inc | Health Care | 0.6% |
| Emergent Biosolutions, Inc. | Health Care | 0.6% |
| Schrodinger Inc/United States | Health Care | 0.6% |
| GW Pharmaceuticals plc | Health Care | 0.6% |
| CRISPR Therapeutics AG | Health Care | 0.5% |
| M3 Inc | Health Care | 0.5% |
| Allogene Therapeutics Inc | Health Care | 0.5% |
| Horizon Pharma plc | Health Care | 0.5% |
| BioNTech SE | Health Care | 0.5% |
| Codexis Inc | Health Care | 0.5% |
| Inari Medical Inc | Health Care | 0.5% |
| Adaptive Biotechnologies Corp | Health Care | 0.5% |
| Krystal Biotech Inc | Health Care | 0.5% |
| Karuna Therapeutics Inc | Health Care | 0.4% |
| Teleflex, Inc. | Health Care | 0.4% |
| Black Diamond Therapeutics Inc | Health Care | 0.4% |
| Constellation Pharmaceuticals Inc | Health Care | 0.4% |
| Stoke Therapeutics Inc | Health Care | 0.4% |
| Morphosys AG | Health Care | 0.4% |
| uniQure NV | Health Care | 0.4% |
| Coherus Biosciences, Inc. | Health Care | 0.3% |
| PTC Therapeutics, Inc. | Health Care | 0.3% |
| NuVasive, Inc. | Health Care | 0.3% |
| Berkeley Lights Inc | Health Care | 0.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Attribution Analysis
| Health Care Fund | Benchmark | Variance | |||||
|---|---|---|---|---|---|---|---|
| Sector | Avg. Weight | Base Return | Avg. Weight | Base Return | Stock Selection | Group Weight | Total |
The total base return displayed for the Fund does not capture daily cash flow and trading activity and therefore is subject to reasonable variance from the Fund's actual return. Please refer to Lord Abbett International Core Fund Performance Results for the Fund's longer-term returns. The Fund is actively managed and portfolio characteristics, such as individual holdings and sector weightings, may change significantly over time.
Source: Wilshire Attribution Software. GICS sector classification; non-GICS securities classified by Lord Abbett. Sectors may include many industries.
Contributors & Detractors as of 09/30/2020
Contributors
| Holding | Contribution |
|---|---|
| Immunomedics Inc | 2.1% |
| Twist Bioscience Corp | 0.8% |
| Abbott Laboratories | 0.6% |
| Danaher Corp. | 0.6% |
| Thermo Fisher Scientifi | 0.6% |
Detractors
| Holding | Contribution |
|---|---|
| Schrodinger Inc | -0.4% |
| Karuna Therapeutics Inc | -0.2% |
| Constellation Pharmceti | -0.2% |
| Vertex Pharmaceutica | -0.2% |
| Gw Pharmaceuticals Plc | -0.2% |
Fees & Expenses
Fees & Expenses
Expense Ratioas of 09/30/2020
| Fund Gross Expense Ratio | Fund Net Expense Ratio | |
|---|---|---|
| 8.67% | 0.70% |
Expense ratio details, Click here.
The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2021. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
Download fund documents & literature, create email subscriptions, and place direct mail order
|
0Documents selected
|
Order | ||||
|---|---|---|---|---|---|
|
Summary Prospectus
Publish Date:11/03/2015
|
|||||
| n/a |
Statutory Prospectus
Publish Date:11/03/2015
|
||||
| n/a |
Prospectus (XBRL)
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
|||||
|
Semi-Annual Report
Publish Date:11/03/2015
|
|||||
|
Fact Sheet
Publish Date:11/03/2015
|
|||||